Robert W. Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock ...
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With ...
Based in Somerset, New Jersey, Catalent, Inc. (CTLT) develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. Valued at a ...
Company broadens service offerings and strengthens network by purchasing Catalent's Center-of-Excellence for Small Molecule Analytical Services facility in North Carolina MINNEAPOLIS, MN ...
MINNEAPOLIS, September 26, 2024 (Newswire.com) - Pace ® Life Sciences, LLC, a contract development, and manufacturing organization (CDMO) and a Division of Pace ®, a Science and Technology Company, ...
Fintel on MSN25d
Baird Downgrades Catalent (CTLT)Fintel reports that on September 24, 2024, Baird downgraded their outlook for Catalent (NYSE:CTLT) from Outperform to Neutral ...
Robert W. Baird analyst Eric Coldwell downgraded the rating on Catalent (CTLT – Research Report) to a Hold today, setting a price target of $63.50. Eric Coldwell has given his Hold rating due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback